An analysis of claims data from more than 7k patients suggests patients with severe obesity and type 2 diabetes who underwent bariatric surgery experienced a 68% reduction in cardiac mortality and 34% reduction in cardiac events compared against standard medical management.
The AHA has released a scientific statement aimed at outlining the current knowledge base related to risk of cardiovascular disease associated with hormonal therapies used in the treatment of breast and prostate cancer.
New data from an analysis of the ISCHEMIA trial is providing insight into the days alive out of hospital with an initial invasive or conservative approach to the management of stable ischemic heart disease.
The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.
Results of 1-year follow-up from the Harmony TPV Clinical trial provide insight into the safety and efficacy of the recently approved Harmony TPV system in patients with congenital heart disease and severe pulmonary regurgitation.
The US FDA announced dapagliflozin (Farxiga) received approval for reducing the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression in a statement on April 30.
An analysis of data from NYU Langone provides perspective into the rapid decline of emergency department presentations for acute myocardial infarction that occurred during the peak of the COVID-19 pandemic.